^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    FUS (FUS RNA Binding Protein)

    i
    Other names: FUS, FUS RNA Binding Protein, TLS, Heterogeneous Nuclear Ribonucleoprotein P2, Translocated In Liposarcoma Protein, 75 KDa DNA-Pairing Protein, RNA-Binding Protein FUS, Fused In Sarcoma, Oncogene FUS, Oncogene TLS, HNRNPP2, FUS1, Fusion (Involved In T(12;16) In Malignant Liposarcoma), Fusion, Derived From T(12;16) Malignant Liposarcoma, Fusion Gene In Myxoid Liposarcoma, Amyotrophic Lateral Sclerosis 6, Translocated In Liposarcoma, Fus-Like Protein, HnRNP-P2, POMP75, POMp75, ALS6, ETM4
    1d
    A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy (clinicaltrials.gov)
    P1/2, N=8, Recruiting, NaviFUS Corporation | Trial completion date: Dec 2025 --> May 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    FUS (FUS RNA Binding Protein)
    1d
    Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM) (clinicaltrials.gov)
    P1/2, N=10, Recruiting, NaviFUS Corporation | Not yet recruiting --> Recruiting | Trial completion date: Mar 2027 --> Mar 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    FUS (FUS RNA Binding Protein)
    |
    Avastin (bevacizumab) • temozolomide
    9d
    VTx-002-01-001: A Phase 1/2 Study of the Safety and Tolerability of ICM VTx-002 in participants with ALS (2025-522697-37-00)
    P1/2, N=2, Not yet recruiting, VectorY Therapeutics B.V.
    New P1/2 trial
    |
    FUS (FUS RNA Binding Protein)
    10d
    "AND" Logic-Gated Biomimetic Nanoparticles to Activate Macrophage Phagocytosis for Cancer Immunotherapy. (PubMed, Nano Lett)
    The hybrid cell-membrane nanovesicles (Fus-CMVs) were constructed by fusing plasma membranes from engineered 293T cells expressing a high-affinity SIRPα variant to block CD47 (Signal A) with membranes from doxorubicin-pretreated 4T1 tumor cells to display CRT (Signal B). In vitro and in vivo studies demonstrated that the "AND" logic-gated Fus-CMVs significantly increased macrophage engulfment of tumor cells and remarkably inhibited tumor growth in different tumor models when compared with single-signal controls. This approach offers a promising approach to enhance macrophage-mediated antitumor immunotherapy.
    Journal
    |
    FUS (FUS RNA Binding Protein) • CALR (Calreticulin) • SIRPA (Signal Regulatory Protein Alpha)
    |
    doxorubicin hydrochloride
    10d
    Morphological and molecular characterization of skeletal and extraskeletal Ewing family of tumors in a tertiary care center of eastern India. (PubMed, Indian J Pathol Microbiol)
    In EFTs, EWSR1 gene rearrangement is most common, followed by FUS gene rearrangement. CD99 immunohistochemistry with additional molecular analysis is essential for further classification of EFTs. A detailed diagnostic algorithm including histology, IHC, and molecular studies is imperative for accurate subcategorization of EFTs.
    Retrospective data • Journal
    |
    EWSR1 (EWS RNA Binding Protein 1) • FUS (FUS RNA Binding Protein) • CD99 (CD99 Molecule) • DUX4 (Double Homeobox 4)
    11d
    Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Peking University People's Hospital
    New trial • Tumor mutational burden • Minimal residual disease
    |
    ABL1 (ABL proto-oncogene 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • JAK2 (Janus kinase 2) • RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • KMT2A (Lysine Methyltransferase 2A) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • NUP98 (Nucleoporin 98 And 96 Precursor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • STAG2 (Stromal Antigen 2) • NSD1 (Nuclear Receptor Binding SET Domain Protein 1) • HOXA9 (Homeobox A9) • NUP214 (Nucleoporin 214) • FUS (FUS RNA Binding Protein) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    NPM1 mutation • MLL rearrangement
    17d
    Superficial Rhabdomyosarcomas: A Review of Subtypes, Diagnostic Features, and Differential Diagnoses. (PubMed, Int J Surg Pathol)
    Recognition of these diverse presentations requires integration of morphologic assessment, immunohistochemistry, and increasingly, molecular diagnostics. Continued clinicopathologic studies and molecular characterization will be essential to refine classification, improve diagnostic accuracy and enhance understanding of the biologic behavior of superficial RMS.
    Review • Journal
    |
    ALK (Anaplastic lymphoma kinase) • EWSR1 (EWS RNA Binding Protein 1) • FUS (FUS RNA Binding Protein) • TFCP2 (Transcription Factor CP2)
    25d
    Valosin-containing protein counteracts ATP-driven dissolution of FUS condensates through its ATPase activity in vitro. (PubMed, FEBS Lett)
    The effect was abolished by the D2-specific inhibitor ML240. Our findings establish direct biochemical evidence that VCP ATPase activity maintains FUS condensates under high ATP conditions, highlighting ATPase-driven enzymatic control of liquid-liquid phase separation as a potential general principle with implications for neurodegeneration.
    Preclinical • Journal
    |
    FUS (FUS RNA Binding Protein)
    29d
    Characterization of Acute Myeloid Leukemia With t(16;21) Translocation: Cytogenetic, Molecular, and Immunophenotypic Findings. (PubMed, World J Oncol)
    The t(16;21)(p11;q22) translocation was the most frequently reported and was frequently associated with CD56 expression. The findings suggest that patients with t(16;21)(p11;q22) exhibited lower 5-year survival compared with the other group, highlighting the unfavorable outcomes observed in reported cases.
    Journal
    |
    RUNX1 (RUNX Family Transcription Factor 1) • CD34 (CD34 molecule) • NCAM1 (Neural cell adhesion molecule 1) • FUS (FUS RNA Binding Protein) • CBFA2T3 (CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3) • ANPEP (Alanyl Aminopeptidase, Membrane)
    1m
    Successful Surgical Treatment of Pediatric FUS::TFCP2-Positive Rhabdomyosarcoma of the Mandible: A Case Report. (PubMed, Int J Surg Pathol)
    The patient had remained disease-free for 18 months. Our experience highlights that early pathological diagnosis and prompt surgical intervention for FUS::TFCP2 fusion-positive RMS are crucial due to its chemoresistance.
    Journal
    |
    FUS (FUS RNA Binding Protein) • TFCP2 (Transcription Factor CP2)
    1m
    FUS is an N1- and N6-methyladenosine-binding protein. (PubMed, Nucleic Acids Res)
    Together, our study underscores a critical role for m1A and m6A in enhancing FUS-RNA interaction, which results in aberrant subcellular distribution and attenuated mobility of the protein in cells. These findings unveil a novel mechanism underlying neurodegenerative disorders emanating from elevated expression of FUS and suggest targeting FUS-methylated adenosine interactions as a potential therapeutic strategy for FUS proteinopathy.
    Journal
    |
    FUS (FUS RNA Binding Protein) • FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO) • METTL3 (Methyltransferase Like 3)